Cartherics granted first patent in China for multiple development candidates

Melbourne, Australia, 09 January 2023Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.

The […]

2023-01-09T14:10:25+11:00January 9th, 2023|

Message from the CEO – December 2022

This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development facility in Notting Hill and are busy completing the preclinical studies for our lead iNK product for treating ovarian cancer. The follow-on product pipeline is revving up with new CAR target candidates, additional gene edits […]

2023-01-20T12:22:20+11:00December 14th, 2022|

Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch

Ian Nisbet and Alan Trounson, AO

Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard to find, and investors are wary of over-promising and under-delivering start-ups, that commonly go aground because of limited resources pitched against the costly demands and long timeframes of drug development.

For public companies, there is often a […]

2022-12-07T16:27:54+11:00December 7th, 2022|

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma

Melbourne, Victoria, Australia – 08 November 2022

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

“Patients with advanced stages of cutaneous T-cell lymphomas often […]

2022-11-09T10:04:56+11:00November 8th, 2022|

Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research

Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for vital ovarian cancer research through the Ovarian Cancer Research Foundation (OCRF).

Ovarian cancer is Australia’s most lethal gynaecological cancer, taking more than 1,000 lives each year. With a five-year survival rate of only 48%, there […]

2022-10-17T11:29:29+11:00October 17th, 2022|

Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria

MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]

2022-11-09T12:37:54+11:00October 13th, 2022|

Cartherics granted first US patent for multiple development candidates

Melbourne, Australia, 06 October 2022Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.

This patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, this patent covers Cartherics’ chimeric […]

2022-10-06T13:32:10+11:00October 6th, 2022|

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.

The company, in […]

2022-09-30T16:02:08+10:00September 30th, 2022|

3 Cheers for a Cartherics Board Member

Bryan Williams ranked among the world’s most prominent scientists

By Leigh Dayton, 16 June 2022

Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to, a prominent academic platform for scientists.

In the recently released edition its […]

2022-06-16T09:19:26+10:00June 16th, 2022|

She’s an Adventurer, Advocate, Author and a Cancer Survivor

Now Heather Hawkins is a member of the Cartherics Board

By Leigh Dayton  9 June 2022

It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.

“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]

2022-06-09T14:44:04+10:00June 9th, 2022|
Go to Top